Mouse CD27-human IgG1 Fc fusion protein
≥ 5.0 mg/ml
< 1.0 EU/mg as determined by the LAL method
≥95% by SDS Page
≥95% monomer by analytical SEC
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Other Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
RM27-3E5 activity is directed against mouse CD27.
CD27 is expressed on T cells, B cells, and NK cells.
CD27 is a glycosylated, type I transmembrane protein of the TNFR superfamily that is constitutively expressed on the surface of progenitor and naïve T cells as well as subsets of natural killer (NK) and B cells1,2. CD27 is an immune-checkpoint receptor and ligation with CD70 results in co-stimulatory effects that enhance primary, memory, and recall T cell responses. CD27 signaling has been targeted for the development of viral, autoimmune, and anti-tumor immunotherapies2.
RM27-3E5 (rat IgG2a) was raised against recombinant mouse CD27-human IgG1 Fc fusion protein and purified from ascites using protein G columns3,4. RM27-3E5 enhances anti-CD3-stimulated T cell proliferation when immobilized in vitro and augments ovalbumin-specific cytotoxic T lymphocyte (CTL) induction when administered in vivo3.
RM27-3E5 is an agonistic antibody3 and has been found to support the control of both established lung metastases and subcutaneous tumors5. An anti-tumor effect was also observed with RM27-3E5 against EG7/CD27(+) and EG7/CD27(−) tumors4, with the effect mediated mainly by T cells with a minor contribution by NK cells. RM27-3E5 exerts its potent anti-tumor effect by inducing a tumor-specific CTL response. RM27-3E5 has potential utility as a non-depleting agonistic anti-CD27 mAb to enhance anti-tumor immunity4.
Associates with CD70
References & Citations
1. Camerini D, Walz G, Loenen WA, et al. J Immunol. 147(9):3165-3169. 1991.
2. Grant EJ, Nüssing S, Sant S, et al. Curr Opin Virol. 22:77-88. 2017.
3. Sumi T, Ishida W, Ojima A, et al. Immunol Lett. 119(1-2):91-96. 2008.
4. Sakanishi T, Yagita H. Biochem Biophys Res Commun. 393(4):829-835. 2010.
5. Roberts DJ, Franklin NA, Kingeter LM, et al. J Immunother. 33(8):769-779. 2010.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.